Abstract
This is a 6 year retrospective analysis of the therapeutic efficacy and safety of Combined Aliskiren (150 mg a day) and Losartan (100 mg a day) in non Diabetic Chronic Kidney Disease (CKD) patients. The objective of this Second (2nd) Phase study was to ascertain the proportion of patients who would remain in remission for the next 3 years and for those who had a relapse of proteinuria after stopping treatment in order to decide when would be an optimum time to stop therapy as well as to ascertain the effects of stopping therapy.
Highlights
In the treatment of Chronic Kidney Disease (CKD) Angiotensin Receptor Blockers (ARBs) reduce proteinuria as well as retard the progression to end stage renal disease [1,2]
A 3 year therapy appears to be an adequate duration for Angiotensin Receptor Blocker (ARB) therapy for proteinuria and though about a third (29%) may relapse, in the majority of cases, proteinuria was less than 0.5 gm/day
Chronic kidney disease, Clinical trial follow up study
Summary
In the treatment of Chronic Kidney Disease (CKD) Angiotensin Receptor Blockers (ARBs) reduce proteinuria as well as retard the progression to end stage renal disease [1,2]. Aliskiren is a direct renin inhibitor which is renal protective. Aliskiren allows for total blockade of the renin angiotensin system and its beneficial effect is independent of BP control [4]. One strategy which has been proven to be effective would be to employ a combination of ARB (Losartan) and Aliskiren as shown in the AVOID Trial by Parving [5]. Such a strategy would achieve the dual purpose of ARB blockade of the RAAS system
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Pathology and Clinical Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
